Taysha Gene Therapies, Inc.
TSHA
$1.76
-$0.06-3.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.02M | 1.79M | 1.11M | 3.41M | 3.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.02M | 1.79M | 1.11M | 3.41M | 3.60M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2.02M | 1.79M | 1.11M | 3.41M | 3.60M |
| SG&A Expenses | 4.03M | 8.79M | 8.21M | 7.08M | 3.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.95M | 22.85M | 22.41M | 27.74M | 19.40M |
| Operating Income | -19.93M | -21.06M | -21.30M | -24.33M | -15.80M |
| Income Before Tax | -18.79M | -25.52M | -20.93M | -24.06M | 47.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.79M | -25.52M | -20.93M | -24.06M | 47.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.79M | -25.52M | -20.93M | -24.06M | 47.74M |
| EBIT | -19.93M | -21.06M | -21.30M | -24.33M | -15.80M |
| EBITDA | -19.63M | -20.77M | -20.98M | -24.01M | -15.43M |
| EPS Basic | -0.07 | -0.10 | -0.09 | -0.10 | 0.23 |
| Normalized Basic EPS | -0.04 | -0.05 | -0.05 | -0.07 | 0.15 |
| EPS Diluted | -0.07 | -0.10 | -0.09 | -0.10 | 0.23 |
| Normalized Diluted EPS | -0.04 | -0.05 | -0.05 | -0.07 | 0.15 |
| Average Basic Shares Outstanding | 268.38M | 267.82M | 232.82M | 231.25M | 210.59M |
| Average Diluted Shares Outstanding | 268.38M | 267.82M | 232.82M | 231.25M | 210.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |